@ -77,11 +77,34 @@ higher if those strategic terminatations were elimintated.
% - In general, there are going to be many confounding variables.
% -
%
%
% van der grong et al 2017 Addressing the challenge of high-price prescription drugs
% Massive number of policies used to try to reduce costs. These will affect production decisions.
% Some of the unintended consequences of that (in terms of reduced development incentives) include
% - reducing development costs - side effect of lower quality evidence
% - Preference policy (e.g. policies about using generics first etc) - side effect of shorter life cycle for patented (novel) drugs.
% - these are focused on reducing expenditures, i.e. they reduce profit. Some of them feed back into the development process.
% -
% Dranov, Garthwaite, and Hermosilla (2022)
% - does the demand-pull theory of R&D explain novel compound development?
% - no, it is biased towards follow-on drug R&D.
% - no, when demand increased (creation of medicare part-D), investement in previously approved drugs grew the most.
% Cerda 2007 - Endogenous innovations in the pharmaceutical industry
% from abstract %TODO: Read better
% Market size, population, and existence of drugs are endogenous
% from the abstract I get the impresssion that it is:
% - large population -> large market -> more profitable -> more drugs
% - more drugs -> better survivability -> larger market
% Applicable because: Need to separate population and market effects.
% Does this mess with my results? I don't think so because of the relatively short time in trials. Not enough time to effect population back, but it might have another effect.
% Dubois et al 2015 - Market Size and pharmaceutical innovation
% from abstract %TODO: Read better
% estimate the relationship between marekt size and the innovation in pharmaceuticals
% elasticity of innovation w.r.t. expected market size of 0.23, thus $2.5 billion in
% market size required to get a new chemical entity.
will king
2 years ago